| Cell Type | Cor.4U human iPSC-derived cardiomyocytes or co-cultures with FibroCor.4U human iPSC-derived cardiac fibroblasts |
| Cell Source | Human iPSC of 26 y/o Caucasian female |
| Service type | Biomechanical analysis |
| Delivery | A study protocol will be sent to initiate the study |
| Timeline | Draft report will be sent within 7 weeks after receipt of test compounds |
| Quotation |
ADVANTAGES
- True force measurement in human iPSC derived cardiomyocytes using proprietary Cor.4CE® assay technology
- Highly precise, standardized and repeatable test system
- Sensitive and predictive for cardiac safety pharmacology
- Suitable for scale-up given low compound volumes, quick turnaround
Read more about this new service also in BioInformants article
Technology overview
The CardioForce cardiac cell contractile force assay is based on the proprietary Cor.4CE® system developed by Axiogenesis, a non-invasive in vitro assay to measure true contractility of cardiomyocyte monolayers or co-cultures of cardiomyocytes with cardiac fibroblasts. Cor.4U® human iPSC-derived cardiomyocytes reveal mechanical properties typical for human cardiac myocytes (Goßmann et al, 2016). The Cor.4CE® system allows for repeatable contractility measurements with unprecedented accuracy under physiological mechanical boundary conditions. In contrast to surrogate technologies like impedance sensing, the Cor.4CE® system shows the expected physiological force-frequency-relationships for adrenergic stimulation.
The combination of Cor.4U with the Cor.4CE® system is the first in vitro assay setup to measure true contractile force of iPSC-derived cardiomyocytes in a system compatible with medium throughput. The system provides an ideal tool to assess pharmacological, safety pharmacological and toxicological effects of drug candidates on human cardiomyocytes.
Force Frequency relationship Graphical analysis. Error bars show standard deviation.
Interested?
Test the assay within a blinded validation: Contact us today!